[go: up one dir, main page]

DK3207938T3 - Ctla-4-varianter - Google Patents

Ctla-4-varianter Download PDF

Info

Publication number
DK3207938T3
DK3207938T3 DK17163638.4T DK17163638T DK3207938T3 DK 3207938 T3 DK3207938 T3 DK 3207938T3 DK 17163638 T DK17163638 T DK 17163638T DK 3207938 T3 DK3207938 T3 DK 3207938T3
Authority
DK
Denmark
Prior art keywords
ctla
variants
Prior art date
Application number
DK17163638.4T
Other languages
English (en)
Inventor
Ralph Minter
Julie Douthwaite
Jacques Moisan
Michael Bowen
Steven Rust
Cyril Privesentzev
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK3207938T3 publication Critical patent/DK3207938T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425Zeins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17163638.4T 2012-05-11 2013-03-11 Ctla-4-varianter DK3207938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
EP13787673.6A EP2863936A4 (en) 2012-05-11 2013-03-11 CTLA-4 VARIANTS

Publications (1)

Publication Number Publication Date
DK3207938T3 true DK3207938T3 (da) 2020-03-16

Family

ID=49551120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17163638.4T DK3207938T3 (da) 2012-05-11 2013-03-11 Ctla-4-varianter

Country Status (17)

Country Link
US (2) US9884902B2 (da)
EP (2) EP2863936A4 (da)
JP (1) JP6228971B2 (da)
KR (1) KR102133060B1 (da)
CN (2) CN104302309B (da)
AU (1) AU2013260172B2 (da)
BR (1) BR112014026718B1 (da)
CA (1) CA2868748C (da)
DK (1) DK3207938T3 (da)
ES (1) ES2777778T3 (da)
HK (1) HK1209644A1 (da)
HU (1) HUE048925T2 (da)
MX (2) MX385969B (da)
PL (1) PL3207938T3 (da)
RU (1) RU2671465C2 (da)
SG (2) SG10201609447XA (da)
WO (1) WO2013169338A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119857A1 (de) 1991-06-17 1992-12-24 Basf Lacke & Farben Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen
JP6228971B2 (ja) * 2012-05-11 2017-11-08 メディミューン,エルエルシー Ctla−4バリアント
SI2867251T1 (sl) * 2012-06-29 2019-12-31 Bristol-Myers Squibb Company Postopki za zmanjšanje agregacije glikoproteina
US9944689B2 (en) * 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
WO2016115275A1 (en) * 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
KR101969513B1 (ko) 2015-08-21 2019-04-16 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
MX2018003144A (es) * 2015-09-14 2018-09-11 Alpine Immune Sciences Inc Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas.
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins and CD80 variants and their uses
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
KR20250083578A (ko) 2017-03-16 2025-06-10 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CA3077509A1 (en) * 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
IL320945A (en) 2017-10-18 2025-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
JP7652422B2 (ja) * 2018-11-02 2025-03-27 ベイジン ブイディージェイバイオ カンパニー, リミテッド 修飾されたctla4およびその使用方法
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
AU2021205976A1 (en) * 2020-01-11 2022-07-07 Yale University Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency
ES2973425T3 (es) 2020-03-26 2024-06-20 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
WO2021207074A2 (en) * 2020-04-06 2021-10-14 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
JP2023523823A (ja) 2020-05-01 2023-06-07 カシーヴ バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー タンパク質の精製の改善されたプロセス
CN112661865A (zh) * 2020-12-31 2021-04-16 厚朴生物科技(苏州)有限公司 针对新型冠状病毒的疫苗以及其应用
AU2022361768A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4448584A4 (en) * 2021-12-17 2025-12-03 Kashiv Biosciences Llc IMPROVED ASSAY METHOD FOR DETERMINING THE POTENCY OF A RECOMBINATING PROTEIN
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0975355A2 (en) * 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
UA87432C2 (uk) * 2000-05-26 2009-07-27 Бристол-Майерс Сквибб Компани Розчинний мутантний ctla4 та його застосування
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007007654A1 (ja) 2005-07-07 2007-01-18 Toshiba Lighting & Technology Corporation 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
RU2506275C2 (ru) * 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
LT3053932T (lt) 2010-02-19 2020-11-10 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
US8642557B2 (en) * 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
JP6228971B2 (ja) * 2012-05-11 2017-11-08 メディミューン,エルエルシー Ctla−4バリアント

Also Published As

Publication number Publication date
US20150104450A1 (en) 2015-04-16
EP3207938B1 (en) 2019-12-25
BR112014026718A2 (pt) 2017-07-18
ES2777778T3 (es) 2020-08-06
US9884902B2 (en) 2018-02-06
CA2868748C (en) 2022-07-26
MX385969B (es) 2025-03-18
EP3207938A2 (en) 2017-08-23
MX2014013092A (es) 2015-03-03
US20180208639A1 (en) 2018-07-26
CN104302309A (zh) 2015-01-21
KR20150014443A (ko) 2015-02-06
KR102133060B1 (ko) 2020-07-10
EP2863936A4 (en) 2016-10-05
CA2868748A1 (en) 2013-11-14
RU2671465C2 (ru) 2018-10-31
EP3207938A3 (en) 2017-11-01
JP6228971B2 (ja) 2017-11-08
BR112014026718B1 (pt) 2021-05-18
CN104302309B (zh) 2017-07-28
SG10201609447XA (en) 2017-01-27
EP2863936A1 (en) 2015-04-29
AU2013260172B2 (en) 2017-11-23
CN107540742A (zh) 2018-01-05
CN107540742B (zh) 2021-06-29
AU2013260172A1 (en) 2014-10-23
RU2014150092A (ru) 2016-07-10
HK1209644A1 (en) 2016-04-08
SG11201405968SA (en) 2014-11-27
MX355234B (es) 2018-04-11
PL3207938T3 (pl) 2020-07-13
WO2013169338A1 (en) 2013-11-14
HUE048925T2 (hu) 2020-09-28
JP2015523328A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
NO2023009I1 (no) Faricimab
NO2021024I1 (no) Inklisiran
NO2019034I1 (no) lorlatinib
DK3207938T3 (da) Ctla-4-varianter
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DK2854722T3 (da) Stomipose
EP2941099A4 (en) SWITCHING DEVICE
EP2831482A4 (en) Flange gasket
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
BR112014022506A2 (pt) variantes de cbh1a
EP2862179A4 (en) FUEL CURRENT INSPECTION PROBE
EP2869113A4 (en) DISPLAY DEVICE FOR VEHICLE